Comparison of novel PSMA-targeting [ < sup > 177 < /sup > Lu]Lu-P17-087 with its albumin binding derivative [ < sup > 177 < /sup > Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study

CONCLUSION: [177Lu]Lu-P17-088 and [177Lu]Lu-P17-087 displayed different pharmacokinetics but excellent PSMA-targeting dose delivery in mCRPC patients. These two agents are promising RLT agents for personalized treatment of mCRPC. Further studies with increased dose and frequency of RLT are warranted to evaluate the potential therapeutic efficacy.TRIAL REGISTRATION: 177Lu-P17-087/177Lu-P17-088 in Patients with Metastatic Castration-resistant Prostate Cancer (NCT05603559, Registered at 25 October, 2022). URL OF REGISTRY: https://classic.CLINICALTRIALS: gov/ct2/show/NCT05603559 .PMID:38658392 | DOI:10.1007/s00259-024-06721-x

Source: Molecular Medicine - April 24, 2024 Category: Molecular Biology Authors: Linlin Li Jiarou Wang Guochang Wang Rongxi Wang Wenbin Jin Jie Zang Huimin Sui Chenhao Jia Yuanyuan Jiang Haiyan Hong Lin Zhu David Alexoff Karl Ploessl Hank F Kung Zhaohui Zhu Source Type: research